CELL AND GENE THERAPY
IsoPlexis | May 26, 2021
IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell.
This is the next step in the company's roadmap, enabling researchers to make far earlier connections in their genomic studies, straight to the proteome, which determines each organism's in vivo dynamic biology. The acquired assets will allow IsoPlexis' proprietary proteomics technologies to be integrated with newer proprietary sequencing-based technologies. The asset acquisition adds to IsoPlexis' ongoing efforts to assist its customers in more effectively simplifying complex biology to accelerate the creation of more personalized and curative advanced medicines from bench to bedside.
Isoplexis' growing patent portfolio of 153 total patents filed and issued globally will now include sequencing methodologies, allowing for a new level of resolution into the connections between the genome and the proteome of cancer immunology, cell and gene therapy, neurological disease, and other areas.
IsoPlexis' proprietary functional proteomics platform is the first to fully characterize and link cellular function to patient outcomes, treatment response, or disease progression using both proteomics and single-cell biology. The single-cell proteomics platform from IsoPlexis, which comprises instruments, chip consumables, and software, offers an end-to-end solution for providing a more complete view of protein function at the cellular level.
The platform has been quickly embraced by the top 15 global biopharmaceutical companies in terms of revenue, as well as over half of the comprehensive cancer centers in the United States, to develop more durable therapeutics, overcome therapeutic resistance, and predict patient responses for advanced immunotherapies, cell therapies, gene therapies, vaccines, and regenerative medicines.
IsoPlexis is a life science technology company that develops solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect to in vivo biology more directly and develop more precise and personalized therapies. Our integrated systems, which were named top innovation or design by Scientist Magazine, Fierce, BIG Innovation, Red Dot, and a variety of other magazines, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been used by researchers all over the world, including the top 15 pharmaceutical companies in the world and 45% of comprehensive cancer centers in the United States.